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ABSTRACT
There is an urgent unmet need for new therapeutics in acute myeloid leukemia 
(AML) as standard therapy has not changed in the past three decades and outcome 
remains poor for most patients. Sphingolipid dysregulation through decreased ceramide 
levels and elevated sphingosine 1-phosphate (S1P) promotes cancer cell growth and 
survival. Acid ceramidase (AC) catalyzes ceramide breakdown to sphingosine, the 
precursor for S1P. We report for the first time that AC is required for AML blast survival. 
Transcriptome analysis and enzymatic assay show that primary AML cells have high 
levels of AC expression and activity. Treatment of patient samples and cell lines with AC 
inhibitor LCL204 reduced viability and induced apoptosis. AC overexpression increased 
the expression of anti-apoptotic Mcl-1, significantly increased S1P and decreased 
ceramide. Conversely, LCL204 induced ceramide accumulation and decreased Mcl-1 
through post-translational mechanisms. LCL204 treatment significantly increased 
overall survival of C57BL/6 mice engrafted with leukemic C1498 cells and significantly 
decreased leukemic burden in NSG mice engrafted with primary human AML cells. 
Collectively, these studies demonstrate that AC plays a critical role in AML survival 
through regulation of both sphingolipid levels and Mcl-1. We propose that AC warrants 
further exploration as a novel therapeutic target in AML.
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INTRODUCTION
Acute myeloid leukemia (AML) is a group of 
heterogeneous hematological diseases [1, 2]. Genetic 
abnormalities such as chromosomal deletions, inversions 
and translocations, as well as molecular alterations in 
hematopoietic stem cells abrogate normal differentiation 
and induce uncontrolled proliferation [3]. AML patients 
generally have high levels of these immature leukemic 
cells, known as blasts, accumulating in the bone 
marrow and peripheral blood with occasional organ 
infiltration. Current first-line cytotoxic chemotherapy 
exhibits limited success, with 50% of younger patients 
and 80% of older patients succumbing to the disease [2, 
4]. Lower survival rates are also observed in patients 
with prior myelodysplastic syndromes (MDS) and prior 
chemotherapy treatments [5]. New therapeutics are under 
development to target specific genetic or molecular 
abnormalities, but these are limited to selected sub-
populations within AML [6]. In this context, it is vitally 
important to discover novel therapeutic targets for a 
broader spectrum of AML patients.
Sphingolipids, a class of bioactive molecules, 
are important in determining cell fate [7]. The balance 
between two major sphingolipid metabolites: pro-apoptotic 
ceramide and pro-survival sphingosine 1-phosphate 
(S1P), has been referred to as the “sphingolipid rheostat” 
[8]. Studies have shown that endogenous ceramide 
functions as a pro-apoptotic lipid messenger when 
induced by radiation, stress, and chemotherapeutic agents 
[9]. Furthermore, increased ceramide levels trigger 
apoptotic cell death in several types of cancer [10], either 
through receptor-mediated caspase activation or through 
mitochondrial-mediated caspase activation involving 
cytochrome c release [11, 12].
Ceramidases are a group of enzyme hydrolases 
within the sphingolipid pathway that metabolize ceramide 
into sphingosine and free fatty acid [10]. Sphingosine 
then serves as a substrate for sphingosine kinase (SphK)-
mediated phosphorylation to form mitogenic S1P. Hence, 
elevated ceramidase activity can reduce endogenous 
ceramide levels, thereby shifting the sphingolipid balance 
to a pro-survival state [13]. Five isoforms of ceramidase 
exist and are optimal in different pH environments: acid 
(ASAH1), neutral (ASAH2) and alkaline (ACER1-3). 
Acid ceramidase (hereafter referred to as AC), which is 
preferentially localized in the lysosome, is essential in 
embryogenesis and in tumor progression [14, 15]. AC is 
highly expressed in solid tumors isolated from prostate, 
melanoma, and breast cancers, as well as leukemia 
including T-cell large granular lymphocytic (LGL) 
leukemia [15–17]. Moreover, targeting AC induces 
programmed cell death (caspase-dependent or independent 
apoptosis) and increases sensitivity to cytotoxic agents 
[18–20].
Dysregulated apoptotic pathways are a common 
characteristic in cancers, including AML [21]. Anti-
apoptotic myeloid cell leukemia sequence 1 (Mcl-
1), a member of the Bcl-2 family, is overexpressed in 
AML [22]. Mcl-1 binds to and inhibits the activation of 
pro-apoptotic Bcl-2 family members, which prevents 
cytochrome c release and apoptosis [23]. Recent 
publications have shown that cancer cells can develop 
resistance to chemotherapeutic drugs and Bcl-2 inhibitors 
through Mcl-1 expression [24]. Furthermore, studies using 
in vivo AML models clearly demonstrated that Mcl-1 is 
essential in AML survival [25].
The present study explored the hypothesis that 
elevated AC plays a critical role in AML survival through 
sphingolipid dysregulation and Mcl-1 induction. We 
demonstrate that AC is upregulated in AML blasts and that 
AC inhibition with the ceramide analog LCL204 increased 
ceramide levels and induced apoptosis. AC inhibition also 
decreased Mcl-1 expression, uncovering a previously 
unknown regulation of Mcl-1. Taken together, these 
studies demonstrate for the first time that AC represents a 
novel and attractive target in AML.
RESULTS
We hypothesized that AC, which is elevated in 
several types of cancer, plays a critical role in AML [26–
28]. Analysis of RNA-Seq data obtained from The Cancer 
Genome Atlas (TCGA, Figure 1A) showed that AML 
patient samples (n=145) have significantly higher (1.7-
fold) AC expression compared to normal bone marrow 
samples (n=5) (FDR<0.05). This is unique only to AC, 
as other ceramidases were not highly or differentially 
expressed in AML patient samples or normal CD34+ bone 
marrow samples. Although ACER3 expression in TCGA 
AML patient samples is significant when compared to 
normal CD34+ bone marrow samples (FDR p<0.01), 
ACER3 expression is relatively low compared to ASAH1 
expression. Independent gene expression microarray 
analysis (Figure 1B) of 30 AML patient samples and 8 
normal CD34+ bone marrow samples verified that AC 
mRNA expression is significantly elevated (1.6-fold) in 
AML patients blasts compared to normal CD34+ bone 
marrow-derived samples (p<0.05, Mann-Whitney U- 
test). Next, we determined whether the observed increase 
in AC gene expression is associated with AC enzymatic 
activity. Samples were taken from 51 newly diagnosed 
AML patients and from enriched CD34+ cells from 12 
normal donors and assayed for AC activity (Figure 1C). 
This screening indicated that 82% of AML patient samples 
tested have significantly higher AC activity compared 
to the mean AC activity of the normal CD34+ controls 
(p=0.0016; Wilcoxon rank sum test). Thus data from 
TCGA, microarray and AC enzymatic activity screening 
all show that AC is elevated in AML patient samples.
Oncotarget83210www.impactjournals.com/oncotarget
To determine whether high AC activity is 
relevant to therapeutic development, we sorted patients 
into high and low AC activity then correlated these 
measures with clinical outcomes. Patients who did not 
receive standard chemotherapy were excluded from 
these analyses. Patients with high AC activity had 
significantly lower overall survival (Supplementary 
Figure S1A, p=0.03, log-rank test) and significantly 
lower relapse-free survival than patients with lower 
AC activity (Supplementary Figure S1B, p=0.01, log-
rank test). Patient distribution was relatively balanced 
among cytogenetic risk groups (Supplementary Figure 
S1C). This finding greatly supports AC’s role in AML 
survival and suggests that it may be a clinically relevant 
biomarker of poor prognosis as well as a therapeutic 
target.
To establish whether this elevated AC expression 
and activity in primary AML cells is crucial to the survival 
of AML blasts, we treated patient cells with increasing 
doses of the AC inhibitor LCL204 [29] and measured 
the effect on AC activity, cell viability and apoptosis. 
Treatment of patient samples with LCL204 led to a dose-
dependent, significant reduction in AC activity (Figure 
2A). Samples from fifteen patients treated with LCL204 
showed a dose-dependent decrease in cell viability (Figure 
2B). Furthermore, 24-hour LCL204 treatment induced 
apoptosis in a dose- (Figure 2C) and time-dependent 
manner (Supplementary Figure S2) in patient samples. As 
AML is a heterogeneous disease, we screened six human 
AML cell lines with different molecular and cytogenetic 
abnormalities to determine the universality of sensitivity 
to LCL204. LCL204 induced dose-dependent apoptosis in 
Figure 1: AC expression and activity are elevated in AML. A. TCGA RNA-Seq gene expression data in 145 AML patients and 
5 CD34+ normal BM samples for ceramidases ASAH1 (acid ceramidase), ASAH2 (neutral ceramidase), ACER1 (alkaline ceramidase 1), 
ACER2 (alkaline ceramidase 2) and ACER3 (alkaline ceramidase 3). Each bar represents mean relative fluorescence units, and error bars 
represent standard error of mean (SEM). *, p<0.05, indicates significant difference of AML patient cells compared to normal CD34+ cells 
(Wald test and Benjamini-Hochberg procedure). B. Microarray analysis of ASAH1, ASAH2, ACER1, ACER2 and ACER3 mRNA levels. 
The mRNA expression in AML patient cells (n =30) was compared to normal CD34+ bone marrow cells from healthy controls (n=8). Each 
bar represents mean relative fluorescence units, and error bars represent standard error of mean (SEM).*, p<0.05, indicates significant 
difference of AML patient cells compared to normal CD34+ cells (Wilcoxon rank-sum test). C. AC activity of normal CD34+ cells (n=12, 
far left, mean ± SEM) and primary AML patient samples (n=51) was measured using flourogenic substrate CB-12. AC activity is elevated 
in the vast majority of AML patient cells compared to normal controls (p=0.0016; Wilcoxon rank sum test). Solid line represents the normal 
mean.
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all six AML cell lines tested, including the drug-resistant 
HL-60 variants HL-60/VCR and HL-60/ABTR (Figure 
2D). Interestingly, AML cell lines were more sensitive to 
AC inhibition with LCL204 (EC50 5.1 µM ± 0.2 SEM, 
n=7) than normal BM CD34+ cells (EC50 6.0 µM, n=1) 
and normal mobilized PBMC CD34+ cells (EC50 7.2 µM ± 
0.4 SEM, n=4). AC activity was also significantly reduced 
with LCL204 treatment in HL-60/VCR starting at 1 µM 
(p<0.05, Student’s t-test) (Supplementary Figure S3). A 
genetic approach was also utilized to further demonstrate 
the critical role of AC in AML survival. HL-60/VCR cells 
were electroporated with AC shRNA. AC expression 
was diminished at 66 hours (Figure 2E top), followed by 
decreased viability at 72 (p<0.05, Student’s t-test) and 
96 hours (p<0.0005, Student’s t-test) post-transfection 
compared to control vector (Figure 2E bottom). These 
results indicate that elevated AC activity is crucial to the 
survival of primary AML blasts and human AML cell 
lines.
We further investigated the mechanism of 
LCL204-induced apoptosis to determine which 
apoptotic regulatory proteins were affected by LCL204 
treatment. Extracts of HL-60/VCR cells treated with 
LCL204 were analyzed for Bcl-2 family expression 
levels (Figure 3A). LCL204 treatment dramatically 
decreased both AC and total Mcl-1 levels, first noted 
at 2 hours post-treatment. Phosphorylated Mcl-1 levels 
decreased at 15 hours post-treatment. However, little to 
no change was observed in other Bcl-2 family members 
(Bcl-2, Bcl-xL and Bax) with LCL204 treatment. 
Publications have shown that SphK1 can regulate 
Mcl-1 [30]; however, LCL204 treatment did not affect 
SphK1 expression (Figure 3A). To recapitulate these 
observations in patient samples, cells from two AML 
Figure 2: AC inhibition reduces viability and increases apoptosis in AML patient blasts and human AML cell lines. 
A-C. AML patient samples were treated with LCL204 for 24 hours. (A) AC activity after LCL204 treatment in AML patient cells. (B) 
Viability and (C) apoptosis assays in LCL204-treated cells were performed as described in the Materials and Methods section. D. LCL204 
treatment (24 hours) led to dose-dependent apoptosis induction in human AML cell lines. VCR: Vincristine resistant, ABTR: ABT-737 
resistant. E. Viability was determined by MTS assay in HL-60/VCR cells electroporated with either control or AC shRNA pLKO.1 vectors. 
(Inset) Blot showing AC knockdown with AC shRNA pLKO.1 vector at 66 hours. *, p<0.05; **, p<0.005; ***, p<0.0005 versus control 
(Student’s t test).
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patients were treated with LCL204 (7.5 µM) in a time-
dependent manner (Figure 3B) or a single dose for 18 
hours (Figure 3C). AC inhibition induced markers of 
apoptosis with increased cleaved PARP and cleaved 
caspase-3 corresponding to the reduction in AC and 
Mcl-1 levels. Pre-treating cells with caspase inhibitor 
z-VAD-fmk (25 µM) or PARP inhibitor olaparib (10 
µM) rescued the LCL204-mediated decrease in viability 
(Figure 3D), showing that caspase-3 and PARP are 
downstream effectors of LCL204-induced apoptosis. 
Both patient and cell line data demonstrated that 
LCL204 decreased AC and Mcl-1 levels and induced 
apoptosis associated with activation of caspase-3.
Because AC inhibition decreased both AC and Mcl-
1 levels with only two hours of treatment, we probed 
further into the mechanism behind the rapid decrease 
in protein levels. Cathepsin B inhibition with Ca-074-
Me prevented the loss of AC protein in LCL204-treated 
cells (Figure 3E), which is in agreement with existing 
evidence of a role for lysosomal proteases in this process 
[29]. Autophagy blockade with V-ATPase inhibitor 
Bafilomycin-A1 (Supplementary Figure S4) and caspase 
inhibition with z-VAD-fmk (Figure 3F) did not restore 
AC or Mcl-1 levels in LCL204-treated cells. However, 
proteasome inhibitor MG132 rescued LCL204-induced 
loss of Mcl-1 but did not rescue loss of AC (Figure 3F). 
Figure 3: AC inhibition induces apoptosis, decreases pro-survival proteins and downregulates AC and Mcl-1. AML cell 
lines were treated with LCL204 and immunoblotted for apoptotic markers, as well as AC and Mcl-1. Band intensity ratios shown above 
the blots were calculated and normalized to β-actin with the first band in each blot as the reference band. A. HL-60/VCR cells treated with 
either DMSO (15 hours) or LCL204 (7.5 µM) for the indicated times. B. AML patient cells treated with either DMSO (15 hour) or LCL204 
(7.5 µM) for the indicated time points (AML patient # 7) and C. for 18h (AML patient #16). D. HL-60/VCR cells were pre-treated with 
z-VAD fmk (25 µM) and olaparib (10 µM) for 1 hour before treating cells with LCL204 (7.5 µM) for 12 hours. Cells were analyzed by 
MTS assay and the data were normalized to DMSO control and reported as percent viability. E. HL-60/VCR cells were pre-treated with 
cathepsin B inhibitor Ca-074-Me (10 µM) for 1 hour, then treated with LCL204 (7.5 µM) for 5 hours. F. HL-60/VCR cells were co-treated 
with LCL204 (7.5 µM) and either pan-caspase inhibitor z-VAD fmk (10 µM) or proteasome inhibitor MG132 (5 µM) for 6 hours. G. HL-
60/VCR cells were treated with DMSO or LCL204 (7.5 µM) for 1 hour, followed by 10 µg/ml cycloheximide (CHX) treatment for the 
indicated amount of time.
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Using cycloheximide to block protein synthesis, LCL204 
reduced AC protein half-life from 380.9 minutes to just 
57.9 minutes (Figure 3G). However, co-treatment of 
HL-60/VCR cells with LCL204 and actinomycin D 
demonstrated that LCL204 did not affect AC mRNA 
degradation rates (Supplementary Figure S5). Hence, 
our data show that short-term LCL204 treatment led to 
post-translational degradation of AC primarily through 
cathepsin B cleavage and Mcl-1 primarily through the 
proteasome.
Several publications have found that Mcl-1 is 
essential for AML blast survival and functions through 
the sequestration of pro-apoptotic Bcl-2 family members 
[31, 32]. Transient knockdown of AC using lentiviral 
pLKO.1-AC shRNA in three AML cell lines also 
decreased Mcl-1 levels (Figure 4A), which verifies that 
LCL204-mediated effects were indeed related to loss of 
AC activity. We also demonstrated that LCL204 treatment 
for 24 hours decreased Mcl-1 mRNA levels dose-
dependently (Supplementary Figure S6). To further study 
the relationship between AC and Mcl-1, we transduced 
HL-60 cells with pLOC-AC expression vector (referred 
hereafter as HL-60/AC). AC overexpression in HL-60 
cells increased both Mcl-1 protein and mRNA expression, 
confirming that AC positively regulates Mcl-1 (Figure 
4B and 4C). Furthermore, AC inhibition in HL-60/AC 
cells with LCL204 treatment also decreased both AC and 
Mcl-1 expression (Figure 4D). Like other AML cell lines 
tested, LCL204 treatment also induced apoptotic markers 
in HL-60/AC cells through caspase-3 and PARP cleavage 
in a time-dependent manner, starting at 12 hours post-
treatment (Figure 4D). To determine whether Mcl-1 is the 
Figure 4: AC activity regulates expression of pro-survival Mcl-1 protein and confers resistance to Bcl-2 inhibition. A. 
AC and Mcl-1 protein levels were detected by western blotting upon lentiviral-mediated AC knockdown in human HL-60/VCR (72 hours), 
HL-60/ABTR (60 hours) and KG1a cell lines (60 hours). Band intensity ratios shown above the blots were calculated and normalized 
to GAPDH or β-actin with the first band in each blot as the reference band. B-C. Increased Mcl-1 expression in HL-60 cells with AC 
overexpression (HL-60/AC) was quantified using (B) western blot and (C) qRT-PCR. D. HL-60/AC cells were treated with either DMSO 
(18 hours) or LCL204 (7.5 µM) for the indicated times and extracts were probed for the indicated proteins. E. HL-60 and HL-60/AC cells 
were treated with selective Mcl-1 and Bcl-2 inhibitors for 48 hours and analyzed for viability. *, p<0.05 versus control (Student’s t test).
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primary mediator of AC-stimulated survival, HL-60/AC 
cells were treated with Mcl-1 inhibitor maritoclax [32] 
and Bcl-2/Bcl-xL inhibitor ABT-737 [33] for 48 hours 
(Figure 4E). HL-60/AC cells were resistant to Bcl-2/Bcl-
xL inhibition relative to parental HL-60 cells, but Mcl-1 
inhibition reduced HL-60/AC cell viability to levels that 
matched HL-60 parental cells with ABT-737 treatment. 
Collectively, these results demonstrate that elevated AC 
enhanced AML blast survival through Mcl-1 upregulation.
AC activity generates sphingosine, which in turn is 
phosphorylated by SphK to form S1P. As AC is elevated 
in AML samples and cell lines, we next determined how 
the sphingolipid content was altered in response to AC 
overexpression. Lipids from HL-60/AC cells exhibited 
decreased pro-apoptotic ceramide C16 and C24 and 
increased pro-survival lipid S1P (Figure 5A). Treatment 
of four human AML cell lines with S1P (0.1 µM) for 24 
hours in Opti-MEM reduced serum medium significantly 
increased viability compared to the vehicle control cells, 
indicating that S1P enhances AML blast survival (Figure 
5B). Conversely, AC inhibition in four AML cell lines 
with LCL204 treatment (7.5 µM) for 12 hours resulted in 
increased total ceramide content (Figure 5C). Among the 
ceramide species analyzed, C16 and C24 ceramides were 
significantly increased in HL-60/VCR cells (Figure 5D). 
Since LCL204 decreased Mcl-1 expression and increased 
ceramide levels, we treated HL-60/VCR cells with C16 
and C24 ceramides for 2 and 8 hours to determine whether 
Figure 5: S1P promotes survival and AC activity regulates sphingolipid profiles in AML cell lines. A. Enhanced survival 
phenotype upon AC overexpression. Pro-apoptotic lipid levels decreased while pro-survival levels were significantly elevated in HL-60/AC 
cells relative to parental cells. B. Exogenous S1P increases viability in AML cell lines. Cell lines were incubated for 24 hours with 0.1 µM 
S1P or vehicle control in Opti-MEM reduced-serum (50%) medium. Viability assay results are normalized to cells incubated with medium 
containing 10% serum. C. Total ceramide levels and D. C16 and C24 ceramides in HL-60/VCR increased with LCL204 treatment (7.5 μM) 
for 12 hours. E. Exogenous ceramide decreased Mcl-1 expression. HL-60/VCR cells were treated with DMSO, C16 ceramide (15 µM) or 
C24 ceramide (2.5 µM) for 2 hours and 8 hours, then Mcl-1 and β-actin levels were determined by western blotting. F-G. LCL204 treatment 
altered sphingosine and S1P levels in human AML cell lines. Cells were incubated with either DMSO or LCL204 (7.5 μM) for 12h and 
(F) sphingosine and (G) S1P levels were quantified by mass spectrometry as described in the Materials and Method section. *, p<0.05; 
**, p<0.005; ***, p<0.0005 versus control (Student’s t test).
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exogenous ceramide affects Mcl-1 protein levels. At both 
time points, C24 ceramide decreased Mcl-1 expression 
(Figure 5E), suggesting that LCL204 treatment stimulates 
Mcl-1 down-regulation through ceramide accumulation. 
LCL204 treatment for 12 hours also generally reduced 
sphingosine and S1P levels in AML cell lines (Figure 5F–
5G). Although LCL204 did not affect SphK1 expression 
(Figure 2A), cells with higher levels of sphingosine had 
increased S1P levels with LCL204 treatment (Figure 5G). 
Thus AC inhibition increased ceramide levels while AC 
overexpression elevated pro-survival S1P. Collectively, 
the lipid analyses after LCL204 treatment show that the 
cytotoxic effects of LCL204 (Figure 2B–2D) correlated 
best with ceramide accumulation rather than S1P loss, 
thus indicating that elevated AC activity is an essential 
protective mechanism to deplete pro-apoptotic ceramide 
in AML.
Our in vitro experiments provided strong evidence 
that elevated AC activity induces survival in AML patient 
blasts and cell lines. We then utilized two established 
AML in vivo preclinical models to demonstrate that AC 
represents a novel target for AML treatment. C1498 
is a syngeneic murine leukemic cell line of C57BL/6 
origin [34]. The C1498 model is an aggressive leukemia 
which has previously been used to test the efficacy of 
chemotherapeutic agents [35, 36]. AC inhibition decreased 
C1498 cell viability in a dose-dependent manner with an 
apparent EC50 of 3 µM (Figure 6A). LCL204 treatment also 
Figure 6: AC inhibition increases survival in a murine AML model and decreases leukemic blasts in a primary human 
AML xenograft model. A. LCL204 treatment (48 hours) reduced viability of C1498 murine AML cells (EC50 = 3.0 µM). B. Western blot 
of C1498 lysates treated with either DMSO (18 hours) or LCL204 (7.5 μM) for the indicated times and probed with antibodies to apoptotic 
markers, AC and Mcl-1. LCL204 treatment induced apoptotic markers and decreased AC and Mcl-1 levels in C1498 cells. C. Median 
survival of C57BL/6 mice engrafted with syngeneic C1498 cells is significantly increased by LCL204 treatment (24 days) compared to 
vehicle-treated (PTD) controls (19 days; p=0.013, log-rank test). D. AC activity of human AML patient cells treated with LCL204 for 20 
hours shows a significant dose-dependent decrease (***, p<0.0005 versus DMSO control (Student’s t test)). E. NSG mice (n=12 per group) 
engrafted with primary human AML cells were treated with vehicle (PTD) or LCL204 (10 mg/kg) for 4 weeks. Leukemic burden (human 
CD45+/total human and mouse CD45+) was monitored by flow cytometry during the course of the treatment and is expressed as the fold 
change relative to the levels at initiation of treatment. LCL204 significantly decreased leukemic burden in leukemic NSG mice compared 
to vehicle-treated (PTD) mice (p=0.038, repeated-measure ANOVA).
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decreased AC and Mcl-1 expression and induced apoptosis 
markers in C1498 cells (Figure 6B) as seen in human 
AML cell lines and patient samples (Figure 3). Maximum 
tolerated dose studies were conducted in C57BL/6 mice, 
and LCL204 showed minimal toxicity at up to 10 mg/kg 
(Supplementary Figure S7). C57BL/6 mice (n=9 per group) 
were engrafted with C1498 cells (1 x 106) and treated with 
LCL204, starting at five days post-engraftment (5 mg/kg, 
administered three times/week, i. p.). Mice treated with this 
AC inhibitor had a significant increase in overall survival 
(24 days) compared to the vehicle control (19 days; 
p=0.013, log-rank test) (Figure 6C).
We then tested the preclinical efficacy of AC 
targeting in NOD scid gamma (NSG) mice engrafted 
with human patient-derived secondary AML cells. The 
NSG model was established to facilitate engraftment of 
human hematopoietic stem cells [37] and has been used 
extensively for studies involving human AML disease 
progression and preclinical therapeutics [38]. In vitro 
LCL204 treatment of this patient’s cells for 20 hours 
(Figure 6D) significantly decreased AC activity (p<0.0005, 
Student’s t test). NSG mice were engrafted with patient-
derived cells and engraftment was confirmed before 
treatment began. Leukemic mice were then treated with 
either vehicle control or LCL204 (10 mg/kg, administered 
three times/week, i. v.) for 4 weeks. LCL204-treated 
mice showed a significantly reduced proportion of 
human leukemic cells (fold change in hCD45) compared 
to vehicle-treated mice (Figure 6E; p=0.038, repeated-
measure ANOVA). Hence, our data from two AML in 
vivo models showed that targeting AC prolonged overall 
survival and decreased leukemic burden.
DISCUSSION
Our findings identify AC as a novel target for 
AML therapeutic development. We show for the first 
time that AC is elevated in AML patient samples, and 
its activity is essential for survival and predictive of 
clinical outcome (Figure 1, 2 and Supplementary Figure 
S1). Current therapeutics exhibit limited efficacy in 
AML patients, especially in the poor prognostic group 
[5, 39]. The enzymes of ceramide metabolism are 
promising therapeutic targets in cancer [40]. AC catalyzes 
the breakdown of ceramide, and together with other 
ceramidases, provides the sole source of endogenous 
sphingosine [41]. Hence, high AC activity in AML 
blasts decreases cellular ceramide levels and increases 
sphingosine levels, which is ultimately converted to S1P 
by sphingosine kinases. AC’s dual role in regulating both 
ceramide and sphingosine levels increases its importance 
in sphingolipid dysregulation. Studies by our group and 
others indicate that there are a multitude of perturbations 
of sphingolipid metabolism in AML, some of which create 
alternative mechanisms of S1P elevation or ceramide 
detoxification. We see that AC activity is elevated in the 
vast majority of AML samples versus control and that AC 
inhibition shows some degree of efficacy in all cell lines 
and patient samples tested thus far. Although identical 
analyses in the TCGA AML cohort showed no prognostic 
significance of AC mRNA expression levels (data not 
shown), our patient cohort showed significant association 
between high AC activity and shorter overall survival as 
well as relapse-free survival, thus establishing AC as a key 
biochemical target in AML.
Elevated AC can stimulate AML survival, and our 
data demonstrate that inhibiting AC reduces the viability 
of AML cells. LCL204 treatment decreased viability by 
inducing apoptosis in AML patient blasts and cell lines 
through the activation of caspase-3 and cleaved PARP. 
These effects were preceded by rapid post-translational 
degradation of AC and Mcl-1. LCL204-mediated release 
of lysosomal cathepsin B and degradation of AC has 
been previously reported [29]. LCL204 treatment led to 
selective loss of Mcl-1 while other Bcl-2 family members 
were unaffected. This degradation was mediated via 
the proteasome and loss of Mcl-1 was recapitulated by 
exogenous ceramide supplementation as well as genetic 
knockdown of AC expression. Overall, our findings 
showed an increased dependence of AML blasts on 
AC-mediated ceramide detoxification and pro-survival 
signals.
Our findings also clearly show that AC inhibition via 
LCL204 significantly increases ceramide levels. LCL204 
treatment increased C16, C24 ceramides and total ceramide 
in all AML cell lines within 12 hours. This strongly 
suggests that ceramide accumulation impairs AML blast 
survival and that the levels are kept low through elevated 
AC activity. LCL204 also decreased sphingosine and S1P 
levels in several AML cell lines. Cell lines with higher 
levels of sphingosine tend to exhibit increased S1P even 
after LCL204 treatment, which is possible since this 
conversion is downstream of AC. Overall, our results 
are consistent with LCL204-mediated AC degradation 
following release of cathepsin B. The loss of AC activity 
prevents ceramide conversion to sphingosine and leads 
to rapid ceramide accumulation that, together with the 
loss of pro-survival Mcl-1, results in robust induction of 
apoptosis. Genetic manipulation through AC knockdown 
also reduces viability in AML cell lines and decreases 
Mcl-1 expression, showing that LCL204 acts primarily 
through AC inhibition rather than off-target effects. 
Conversely, AC overexpression increases pro-survival 
lipids by decreasing total ceramide levels and increasing 
S1P levels. Our results reflect on the heterogeneity of 
AML by showing that different patients or AML cell lines 
exhibit varying response to AC inhibition. Taken together, 
we provide strong evidence that AC activity enhances 
AML blast survival, and demonstrate for the first time that 
targeting AC reverses the aberrant AML lipid profile of 
low ceramide levels and elevated S1P, which ultimately 
leads to cell death.
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Our data demonstrate that AC regulates Mcl-
1 to induce survival in AML. Mcl-1 has been shown 
to prolong blast survival in AML mouse models and is 
highly expressed in AML blasts [25, 42]. Here, we report 
decreased Mcl-1 protein expression with AC inhibition 
or knockdown as well as loss of Mcl-1 with ceramide 
treatment. Several publications have recently shown that 
targeting Bcl-2 and Bcl-xL using Bcl-2 family inhibitors 
decreased survival of AML patient cells and cell lines 
[43–45]. Our data show that LCL204 did not affect other 
Bcl-2 family members, and we did not uncover any 
direct relationship between AC and other Bcl-2 family 
members. The mechanism by which elevated AC activity 
affects AML survival through Mcl-1 expression could 
be explained through the “sphingolipid rheostat” [8]. 
Ceramide can reduce Mcl-1 expression or inactivate Mcl-
1 [46–49]. Our data showed that exogenous C24 ceramide 
reduced Mcl-1 expression to a greater extent than pro-
apoptotic C16 ceramide, which suggest a role for long chain 
ceramides in apoptotic regulation. In addition, previous 
studies indicate that Mcl-1 binding to BAK modulates 
the ability of BAK to regulate ceramide synthase activity, 
which may represent yet another interplay between 
sphingolipid metabolism and apoptotic pathways [50, 
51]. The reduced ceramide levels associated with AC 
overexpression corresponded with higher S1P levels. S1P 
has been shown to act as a co-factor for E3 ubiquitin ligase 
TRAF2, which leads to the activation of NF-κB, a direct 
and indirect regulator of Mcl-1 [52–55]. Further studies 
are needed to thoroughly explore mechanisms underlying 
AC’s regulation of Mcl-1 and potential effects of AC 
overexpression on mRNA stability, protein translation or 
post-translational events.
Targeting AC increases overall survival of C1498 
leukemic mice and decreases leukemic burden in 
patient-derived leukemic NSG mice. Furthermore, our 
murine in vivo and human in vitro data also suggest a 
therapeutic window for LCL204 as AML cells exhibit 
higher sensitivity to LCL204 than normal counterparts as 
minimal toxicity was observed. This is an exciting finding 
for AML therapeutics. Future experiments will extend 
these findings to determine effects on overall survival 
with multiple AML patient samples of varying clinical and 
molecular subtypes in the NSG mouse model.
Our data clearly indicate that AC expression and 
activity are elevated in AML, which dysregulates the 
sphingolipid rheostat, and demonstrate that AC is a 
novel therapeutic target in AML. Elevated AC activity 
also upregulates Mcl-1 to induce survival in AML blasts, 
and our data show that targeting AC decreased Mcl-
1 levels as well as increased ceramide levels in AML 
cells to induce cell death. Therefore, future clinically 
approved AC inhibitors may be utilized in synergy with 
existing treatment to enhance therapeutic response in 
AML patients. As AML is a heterogeneous group of 
hematological malignancies, further delineation of the 
molecular and cytogenetic classification(s) of AML 
patients that exhibit elevated AC activity could identify 
subgroups that may benefit most from AC-targeted 
treatments.
MATERIALS AND METHODS
Patient samples, cell lines, and inhibitors
All AML patient samples with 20% or greater 
blast count were collected with signed informed consent 
according to a protocol approved by the Institutional 
Review Board of the Milton S. Hershey Medical Center. 
Patients were categorized into cytogenetic risk groups 
based on published guidelines [56]. Human G-CSF 
mobilized PBMC samples from healthy donors were 
obtained from the Blood Bank (Milton S. Hershey 
Medical Center). PBMCs were enriched using the 
Ficoll-Paque gradient separation method (Pharmacia 
Biotech, Piscataway, NJ). CD34+ cells were isolated 
from PBMCs with a CD34+ microbead kit (Miltenyi 
Biotec, Cambridge, MA). CD34+ bone marrow cells from 
normal donors were purchased from All Cells, LLC. 
(Emeryville, CA).
HL-60, KG-1, KG-1a, C1498 and Kasumi-1 were 
purchased from American Type Culture Collection (ATCC, 
Manassas, VA). The ABT-737-resistant HL-60 (HL-60/
ABTR) cells were generated as previously described 
[32]. Vincristine-resistant HL-60/VCR cells were selected 
as previously described [57]. Kasumi-1 was grown in 
RPMI-1640 (Invitrogen, Carlsbad, CA) supplemented 
with 20% FBS from Hyclone (Thermo Fisher Scientific, 
Waltham, MA). KG1 and KG1a were grown in IMDM 
supplemented with 20% FBS. All other cell lines were 
grown in RPMI-1640 supplemented with 10% FBS. In 
addition, HL-60/VCR cells were maintained in medium 
containing 2 µg/ml vincristine. All cells were grown in a 
37°C humidified, 5% CO2 atmosphere incubator. All cell 
lines were authenticated using short tandem repeat DNA 
profiling (Genetica DNA laboratories) at the completion 
of studies.
LCL204 [(1R,2R) 2-(N-tetradecylamino)-1-(4-NO2)-
phenyl- 1,3-dihydroxy-propane HCl] was synthesized as 
previously described [29]. CB-12 was kindly provided 
by Dr. Gemma Fabrias (IQAC-CSIC, Barcelona, Spain) 
[58]. Marinopyrrole A (maritoclax) was synthesized as 
previously described [32, 59]. ABT-737, MG132, z-VAD-
fmk, actinomycin D and Ca-074-Me were purchased 
from Selleckchem (Houston, TX). Cycloheximide was 
purchased from Sigma-Aldrich (St. Louis, MO).
AC activity
AC activity was measured by the accumulation of 
the fluorescent umbeliferone product from the substrate 
CB-12 as previously described [58]. Cells (2 x 104) were 
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incubated in RPMI-10% FBS containing 16 µM of CB-
12 for 3 hours at 37°C. The reaction was stopped by 
adding 50 µl of 100% methanol and 100 µl of 2.5 mg/ml 
sodium periodate in 100 mM glycine, pH 10.6. Cells were 
incubated at 37°C for an additional 2 hours. Fluorescence 
was measured in the UV range using a Synergy HT plate 
reader (Biotek, Winooski, VT) and normalized to blank 
reading of RPMI-10% FBS and fluorogenic substrate. AC 
activity is presented as mean fluorescence unit per 20,000 
cells.
Ceramidase gene expression: RNA-Seq and 
microarray
RNA-Seq: average gene expression from TCGA 
AML patients and 5 normal CD34+ BM controls was 
expressed as a mathematical mean and standard error 
of normalized read counts as provided by DESeq2 [60]. 
Significance for differential expression was determined by 
DESeq2 using the Wald test (default significance test), and 
adjusted for multiple hypothesis testing using Benjamini-
Hochberg FDR [61] across all genes tested.
Microarray: Total RNA was harvested from 30 
AML patient samples and 8 CD34+ bone marrow samples 
from healthy donors (All Cells) using TRIzoL Reagent 
(Invitrogen) according to the manufacturer’s instructions. 
Gene expression analysis was carried out using Illumina 
Human HT-12 V.3 Expression BeadChip (Illumina, San 
Diego, CA). The beadarray expression data were imported 
and quantile-normalized using the R statistical computing 
environment and the beadarray Bioconductor package. 
Hybridization data and parameter information can be 
accessed in the Gene Expression Omnibus (GEO) database 
(http://www.ncbi.nlm.nih.gov/geo). The GEO platform 
accession number is GSE65409. The Illumina CHP and 
CEL file accessions are GSM1595702-GSM1595739. 
Expression data for ASAH1, ASAH2 and ASAH3 probes 
were averaged and graphed as relative fluorescence units.
In vitro apoptosis assay
Cells 2.5 x 105 were treated with DMSO (final 
concentration less than 1% of total volume) or LCL204 
at various doses and time points. Cellular apoptosis 
was quantified by flow cytometry using Annexin 
V-FITC (BD Pharmingen, San Diego, CA) following 
the manufacturer’s protocol. 7-amino-actinomycin D 
(7-AAD; BD Pharmingen) was used to determine dead 
cells. Flow cytometry was done on the BD FacsCalibur. 
The percentage apoptosis was calculated based on the 
Annexin-V-FITC positive population.
In vitro viability assay
Cells 2 x 104 were plated in a 96-well plate and 
incubated with drug or DMSO control (less than 1% 
of final volume) for the indicated time points. For 
experiments using z-VAD-fmk and olaparib, cells were 
pre-treated with the inhibitors for 1 hour before LCL204 
or DMSO treatment. All viability assays were measured 
using CellTiter 96 Aqueous One Solution assay kit 
(Promega, Madison, WI) according to the manufacturer’s 
protocol. The absorbance of the formazan product at 490 
nM was determined using a BioTek Synergy HT plate 
reader.
For S1P-treatment assays, cells were cultured 
in Opti-MEM Reduced Serum Medium (with 50% 
reduced serum supplementation) (Invitrogen) for 30 
hours. S1P (Cayman Chemicals, Ann Arbor, MI) was 
first dissolved in methanol to make a 1 mM stock then 
diluted in BSA solution (32 mg/ml) to 125 µM for MTS 
assays. Methanol-BSA solution (final concentration 1.04% 
methanol) was used as vehicle control for the experiment. 
Absorbances were normalized to cells incubated with 
medium containing 10% serum and recorded as percentage 
viability.
Real-time quantitative RT-PCR
Real-time quantitative reverse transcription 
polymerase chain reaction (qRT-PCR) was performed 
using primer sets specific for human ASAH1 and MCL1, 
with Beta-2- microglobulin (B2M) or 18S as internal 
standards in an ABI PRISM 7900 sequence detector. Total 
RNA was harvested from cells using TRIzoL Reagent 
(Invitrogen) following the manufacturer’s protocols. 
cDNA was synthesized using random hexamers and 
MMLV reverse transcription reagent (Invitrogen). 
Amplification of the cDNA was performed in triplicate 
using Quantitect SYBR Green PCR kit (Qiagen) following 
the manufacturer’s instructions. Primer sequences are as 
follows: ASAH1 sense 5’-TGT GGA TAG GGT TCC 
TCA CTA GA-3’, antisense 5’-TTG TGT ATA CGG TGA 
GCT TGT TG-3’; MCL1 sense 5’-CAA GGG AAG CTT 
TTC CTC TC-3’, antisense 5’-CAT GGA AAC CAA 
GCC AAA GT-3’; B2M sense 5’-TGC TGT CTC CAT 
GTT TGA TGT ATC T-3’, antisense 5’-TCT CTG CTC 
CCC ACC TCT AAG T-3’; 18S sense 5’-GTA ACC CGT 
TGA ACC CCA TT-3’, antisense 5’-CCA TCC AAT CGG 
TAG TAG CG-3’. All primers were supplied by IDTDNA 
(Coralville, IA).
Overexpression and knockdown of AC via 
lentiviral transduction and transfection
AC-expressing plasmid pLOC-AC was purchased 
from Open Biosystems (Thermo Scientific) and was 
transfected into HEK293-FT cells with lentiviral 
packaging plasmids (Invitrogen). Viral particles were 
added to cells every 12 hours for 3 days with 6 µg/ml 
polybrene. Transduced cells were selected with 6 µg/
ml of Blasticidin S for 2 weeks. For AC knockdown, 
plasmid pLKO.1 containing AC shRNA sequences 
(Mission; Sigma-Aldrich) was used following the same 
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protocol. Lysates were harvested 60 to 90 hours post-
transduction. Neon® transfection system (Invitrogen) 
was used to electroporate pLKO.1 plasmids according to 
manufacturer’s protocols.
Western blot analysis
Cells were lysed using RIPA buffer containing 
phosphatase inhibitor cocktail 2 and protease inhibitor 
P8340 according to the manufacturer’s protocol 
(Sigma), resolved on 4-12% SDS-PAGE gels and 
transferred onto PVDF membranes (Millipore, Billerica, 
MA). Primary antibodies used in this study are as 
follows: AC (BD Biosciences), AC (Aviva Systems 
Biology; San Diego, CA), anti-murine Mcl-1 (Rockland; 
Gilbertsville, PA), and from Cell Signaling (Danvers, 
MA): Bcl-2 (#4223), Mcl-1 (#5453), phospho-Mcl-1 
(#4579), Bax (#5023), Bcl-xL (#2764), PARP (#9532), 
SPHK1 (#12071), Caspase-3 (#9662), GAPDH (#2118) 
and Beta-actin (#3700). For secondary antibodies, 
HRP-conjugated goat anti-mouse or goat anti-rabbit 
IgG (Cell Signaling) was used and Pierce Enhanced 
Chemiluminescence (Thermo Scientific) was applied 
to blots according to manufacturer’s protocol. Image 
Processing and Analysis in Java (Image J) software was 
used to measure band density. Each band density was 
normalized to GAPDH or β-actin with the first band in 
each blot as the reference band.
Lipid extraction and analysis by electrospray 
ionization-tandem mass spectrometry
Sphingolipids were analyzed by LC/ESI-MS/MS 
based on the method described with some modifications 
as described below [62]. Lipids were extracted from 
cell pellets (equivalent to 600 μg to 1 mg of protein 
depending on the experiment) using an azeotrophic 
mix of isopropanol:water:ethyl acetate (3:1:6; v:v:v). 
Internal standards (50 pmol of d17 long-chain bases 
and C12 acylated sphingolipids) were added to samples 
at the onset of the extraction procedure. Extracts were 
separated on an Agilent 1100 HPLC system. Mobile 
phases were as described [62], but with 0.2% formic acid 
on a Phenomenex Luna C8 (3 μm) 2.1 mm ID × 5 cm 
column maintained at 60°C for separation of the sphingoid 
bases and 1-phosphates or a Supelco 2.1 mm ID x 5 cm 
NH2 column for acylated sphingolipids. The eluate 
was analyzed with an inline ABI 4000 Q Trap (SCIEX, 
Framingham, MA) mass spectrometer equipped with a 
turbo ion spray source. Mass spectrometry settings were 
set to compensate for differences in ionization efficiency 
of different acyl chain lengths. The peak areas for the 
different sphingolipid subspecies were compared with 
that of the internal standards with 13C isotopic signals 
compensated for where necessary. All data reported 
are based on monoisotopic mass and are represented as 
pmol/mg protein.
Exogenous ceramide assay
C16 and C24 (Avanti) were dissolved in 100% 
Methanol and then diluted 98:2 (v/v) into dodecane. HL-
60/VCR cells were plated at 1 x 106 cells per ml in RPMI 
medium supplemented with 10% FBS. The cells were 
treated with ceramide for 2 hours and 8 hours, after which 
the cells were harvested for western blot.
C57BL/6 and NSG mouse in vivo models
To generate the in vivo C1498 murine AML model, 
1 x 106 C1498 cells were injected retro-orbitally into 
syngeneic eight-week-old female C57BL/6J mice (Jackson 
Labs, Bar Harbor, ME) [63]. LCL204 was dissolved in 
30% v/v propylene glycol, 5% v/v Tween 80 and 65% of 
5% w/v dextrose in water (PTD). Five days after C1498 
engraftment, 5 mg/kg of LCL204 or PTD vehicle was 
injected i.p. every 2 days for a total of 10 injections. The 
amount of LCL204 administered was based upon two 
maximum tolerated dose studies and the regimen was 
based on a previously published method [28]. Mice with 
20% body weight loss were considered to have significant 
leukemic burden and were euthanized.
Twenty-four female NSG (NOD.Cg-Prkdcscid 
Il2rgtm1Wjl/SzJ) mice (6-8 week-old, Jackson Laboratory) 
were sub-lethally irradiated (200 cGy) the day before 
intravenous injection of 5.5 x 105 patient-derived 
secondary AML cells. Five months following injection, 
AML engraftment was confirmed and the mice were 
randomly divided into two groups and treated with 10 mg/
kg LCL-204 i.v. or vehicle control PTD thrice a week for 
4 weeks. Blood was collected to monitor the tumor burden 
at different time points. CD45-FITC (BD 555482), CD33-
PE (BD 555450), CD19-APC H7 (BD 560727), CD3-PE 
Cy7 (BD 557851), HLA DR-PerCP Cy5.5 (BD 560652), 
CD117-BV421 (BD 562434), and mCD45-BV650 (BD 
563410) were used to determine leukemia burden by 
flow cytometry (LSR-II, BD Biosciences). The leukemia 
burden was calculated as number of human CD45 positive 
cells/ (total number of human CD45 positive cells + 
mouse CD45 positive cells) x 100. All animal studies were 
conducted in accordance with the guidelines approved by 
the Institutional Animal Care and Use Committee at The 
Pennsylvania State University, College of Medicine.
Statistical analyses and experimental design
Statistical analyses between two treatment groups 
were performed with Student’s t-test. Mann-Whitney U- 
test was used in the microarray analysis and Wilcoxon 
rank sum test was used in the AC activity screening 
analysis. Other statistical tests used were described 
alongside individual experiments in the materials and 
methods, figure legends and results sections. Each graph 
was presented as an average of three replicates and 
error bars represent standard error of mean (SEM). For 
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in vitro assays using cell lines, results were from two or 
more independent experiments, unless otherwise noted. 
Due to the limitation of primary samples, data from 
primary patient and normal donor samples were from one 
independent experiment.
Supplementary information is available at 
Oncotarget’s website.
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